Evidence map›Paper›PMID 34641612›Full record

ArticleMolecules (Basel, Switzerland)2021

Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs.

Athanasios A Panagiotopoulos, Ioannis Karakasiliotis, Danai-Maria Kotzampasi, Marios Dimitriou, George Sourvinos, Marilena Kampa, Stergios Pirintsos, Elias Castanas, Vangelis Daskalakis

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Computational andFrontiers in pharmacology · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Athanasios A PanagiotopoulosLaboratory of Experimental Endocrinology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Ioannis KarakasiliotisLaboratory of Biology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0003-3004-8104
Danai-Maria KotzampasiLaboratory of Experimental Endocrinology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Marios DimitriouLaboratory of Biology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
George SourvinosLaboratory of Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Marilena KampaLaboratory of Experimental Endocrinology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Stergios PirintsosNature Crete Pharmaceuticals, 71305 Heraklion, Greece.
Elias CastanasLaboratory of Experimental Endocrinology, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0002-8370-1835
Vangelis DaskalakisDepartment of Chemical Engineering, Cyprus University of Technology, 3603 Limassol, Cyprus.ORCID 0000-0001-8870-0850
University of Crete · GRDemocritus University of Thrace · GRCyprus University of Technology · CY

Funding

European Social Fund MIS-5000432Hellenic Foundation for Research and Innovation 3725Partnership for Advanced Computing in Europe AISBL Epitope vaccines based on the dynamics of mutated SARS-CoV-2 proteins at all atom resolution
6 · The paper itself

Abstract

3CL-Pro is the SARS-CoV-2 main protease (MPro). It acts as a homodimer to cleave the large polyprotein 1ab transcript into proteins that are necessary for viral growth and replication. 3CL-Pro has been one of the most studied SARS-CoV-2 proteins and a main target of therapeutics. A number of drug candidates have been reported, including natural products. Here, we employ elaborate computational methods to explore the dimerization of the 3CL-Pro protein, and we formulate a computational context to identify potential inhibitors of this process. We report that fortunellin (acacetin 7-

Indexed as

COVID-19 Drug TreatmentAnimalsAntiviral AgentsChlorocebus aethiopsCoronavirus 3C ProteasesFlavonoidsGlycosidesHumansMolecular Docking SimulationPolyphenolsProtease InhibitorsProtein MultimerizationSARS-CoV-2Vero Cells3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesFlavonoidsfortunellinGlycosidesPolyphenolsProtease InhibitorsCOVID-19metadynamicsmolecular simulationsnatural productsSARS-CoV-2

Identifiers

PMID34641612
PMCPMC8512273
OpenAlexW3201920406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.